There are few studies reporting the association of BRCA2 mutations with immune biomarkers in tumors such as gastroesophageal cancers [75] or with an immunogenic microenvironment in ovarian cancers [76]. This evidence concerns the gene BRCA2 and ovarian carcinoma.